Paxlovid (Nirmatrelvir with ritonavir): Supply issue resolved

Due to an increase in cases of COVID-19, supply of Paxlovid was low earlier in December. There is now sufficient supply available.

Update 5 January 2024

More stock of Paxlovid has arrived in New Zealand. The expiry of this batch of Paxlovid (nirmatrelvir 150 mg/ritonavir 100 mg), batch number GJ2963, has been extended to March 2024. 

Letter to pharmacists about the shelf-life extension of Paxlovid [PDF, 165 KB] 

Affected product

Paxlovid is the brand name of mirmatrelvir with ritonavir. It is currently the most widely used treatment for COVID-19 in Aotearoa New Zealand. There was limited stock available during December 2024. Use of the treatment has increased due to a rise in COVID-19 cases.

Schedule listing for Paxlovid(external link)

Access criteria for COVID-19 antivirals

Information for prescribers

Please continue to prescribe Paxlovid as normal.

We know that managing supply issues can be time consuming at the best of times, and this is a very busy time of year. We appreciate your time and effort.

Future deliveries 

We will work as hard as possible to get the stock New Zealand needs as soon as possible. 

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.  

Sign up to our email list for regular emails about supply issues and more(external link)